51. Scleroderma Clinical trials / Disease details

Clinical trials : 525 / Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217

8 trials found

diseases per page:

Showing 1 to 8 of 8 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2014-001882-28-DE (EUCTR)	13/10/2014	07/08/2014	Drug treatment of patients with systemic sclerosis to prevent deterioration of pulmonary hypertensio ...	Early Treatment of Borderline Pulmonary Arterial Hypertension Associated with Systemic Sclerosis (SS ...	Systemic sclerosis-patients (SSc) with borderline pulmonary arterial hypertension;Therapeutic area: ...	Trade Name: Volibris Product Name: Ambrisentan	Thoraxklinik-Heidelberg gGmbH	NULL	Not Recruiting			Female: yes Male: yes	38	Phase 2	Germany
2	NCT02290613 (ClinicalTrials.gov)	July 1, 2014	31/10/2014	Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SS ...	Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SS ...	Systemic Sclerosis;Pulmonary Hypertension	Drug: Ambrisentan;Drug: Placebo	Heidelberg University	GlaxoSmithKline	Completed	18 Years	N/A	All	38	Phase 2	Germany
3	NCT02169752 (ClinicalTrials.gov)	September 2012	6/5/2014	Ambrisentanfor the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arter ...	Ambrisentanfor the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arter ...	Pre-Pulmonary Atrial Hypertension	Drug: Ambrisentan	National Jewish Health	NULL	Terminated	18 Years	80 Years	All	7	N/A	United States
4	NCT01072669 (ClinicalTrials.gov)	February 2010	19/2/2010	Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet	Evaluation of the Effect of Ambrisentanon Digital Microvascular Flow in Patients With Systemic Scler ...	Ischemia	Drug: ambrisentan	Soumya Chatterjee	Gilead Sciences	Completed	18 Years	70 Years	All	20	N/A	United States
5	NCT01093885 (ClinicalTrials.gov)	February 2010	24/3/2010	Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis	An Open Label Study of AmbrisentanWith Antifibrotic Agent Combination Therapy in Treatment of Diffus ...	Systemic Sclerosis;Scleroderma	Drug: Ambrisentan	University of Pennsylvania	Gilead Sciences	Completed	19 Years	90 Years	All	15	N/A	United States
6	NCT01042158 (ClinicalTrials.gov)	January 2010	4/1/2010	A Clinical Trial of Ambrisentanand Tadalafil in Pulmonary Arterial Hypertension Associated With Syst ...	A Clinical Trial of Ambrisentanand Tadalafil in Pulmonary Arterial Hypertension Associated With Syst ...	Pulmonary Arterial Hypertension;Systemic Sclerosis;Scleroderma Spectrum of Diseases;Connective Tissu ...	Drug: tadalafil and ambrisentan upfront combination therapy	Johns Hopkins University	National Institutes of Health (NIH);National Heart, Lung, and Blood Institute (NHLBI);Eli Lilly and ...	Completed	18 Years	N/A	All	25	Phase 4	United States
7	NCT01051960 (ClinicalTrials.gov)	March 2009	19/1/2010	Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan	Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan: A Pros ...	Systemic Sclerosis;Shortness of Breath;Pulmonary Hypertension	Drug: Ambrisentan	University of California, Los Angeles	Gilead Sciences	Completed	18 Years	80 Years	All	12	Phase 4	United States
8	NCT00725361 (ClinicalTrials.gov)	June 2008	28/7/2008	A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ul ...	A Pilot Study to Evaluate the Efficacy of Ambrisentanin the Treatment and Prevention of Digital Ulce ...	n Ulcer;Scleroderma, Systemic	Drug: Ambrisentan	Stanford University	NULL	Completed	18 Years	N/A	All	20	N/A	United States

First Previous1Next Last